Folate-conjugated human serum albumin-encapsulated resveratrol nanoparticles: preparation, characterization, bioavailability and targeting of liver tumors

References

• Wang H-D, Shi Y-M, Li L, et al. Treatment with resveratrol attenuates sublesional bone loss in spinal cord-injured rats. Br J Pharmacol. 2013;170:796–806. doi:10.1111/bph.12301. PubMed PMID: WOS:000325139400009.
   PubMed Web of Science ®Google Scholar
• Singh NP, Hegde VL, Hofseth LJ, et al. Resveratrol (trans-3,5,4′-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol. 2007;72:1508–1521.
   PubMed Web of Science ®Google Scholar
• Koul D, Shen R, Bergh S, et al. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther. 2006;5:637.
   PubMed Web of Science ®Google Scholar
• Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle. 2008;7:1020–1035.
   PubMed Web of Science ®Google Scholar
• Colin D. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets. 2006;7:423–442.
   PubMed Web of Science ®Google Scholar
• Carter LG, D’Orazio JA, Pearson KJ. Resveratrol and cancer: focus on in vivo evidence. Endocr Relat Cancer. 2014;21:R209.
   PubMed Web of Science ®Google Scholar
• Venkatadri R, Muni T, Iyer AKV, et al. Role of apoptosis-related miRNAs in resveratrol-induced breast cancer cell death. Cell Death Dis. 2016;7:e2104.
   PubMed Web of Science ®Google Scholar
• Mattarei A, Azzolini M, Carraro M, et al. Acetal derivatives as prodrugs of resveratrol. Mol Pharmaceutics. 2013;10:2781–2792.
   PubMed Web of Science ®Google Scholar
• Deng R, Yi H, Fang Y, et al. Facile exfoliation of MoS2 nanosheets by protein as a photothermal-triggered drug delivery system for synergistic tumor therapy. RSC Adv. 2016;6:77083–77092.
   Web of Science ®Google Scholar
• Singh G, Pai RS. In-vitro/in-vivo characterization of trans-resveratrol-loaded nanoparticulate drug delivery system for oral administration. J Pharm Pharmacol. 2014;66:1062–1076.
   PubMed Web of Science ®Google Scholar
• Loira-Pastoriza C, Todoroff J, Vanbever R. Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev. 2014;75:81.
   PubMed Web of Science ®Google Scholar
• Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132:171.
   PubMed Web of Science ®Google Scholar
• Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012;157:168–182.
   PubMed Web of Science ®Google Scholar
• Bokharaei M, Margaritis A, Xenocostas A, et al. Erythropoietin encapsulation in chitosan nanoparticles and kinetics of drug release. Curr Drug Deliv. 2014;8:164–171.
   Web of Science ®Google Scholar
• Kouchakzadeh H, Shojaosadati SA, Tahmasebi F, et al. Optimization of an anti-HER2 monoclonal antibody targeted delivery system using PEGylated human serum albumin nanoparticles. Int J Pharm. 2013;447:62–69.
   PubMed Web of Science ®Google Scholar
• Wei T, Du D, Wang Z, et al. Rapid and sensitive detection of microRNA via the capture of fluorescent dyes-loaded albumin nanoparticles around functionalized magnetic beads. Biosens Bioelectron. 2017;94:56–62.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. Cancer. 2002;55:74–108.
   Google Scholar
• Zhu B, Sun L, Luo W, et al. Activated Notch signaling augments cell growth in hepatocellular carcinoma via up-regulating the nuclear receptor NR4A2. Oncotarget 2017;8:23289–23302.
   PubMedGoogle Scholar
• Yang YW, Yang L, Zhang C, et al. Physagulide Q suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells by regulating the ROS-JAK2/Src-STAT3 signaling pathway. RSC Adv. 2017;7:12793–12804.
   Web of Science ®Google Scholar
• Ciacio O, Voron T, Pittau G, et al. Interest of preoperative immunonutrition in liver resection for cancer: study protocol of the PROPILS trial, a multicenter randomized controlled phase IV trial. BMC Cancer. 2014;14:1–10.
   PubMed Web of Science ®Google Scholar
• Turk MJ, Reddy JA, Chmielewski JA, et al. Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs. Biochim Biophys Acta. 2002;1559:56.
   PubMed Web of Science ®Google Scholar
• Reddy JA, Dean D, Kennedy MD, et al. Optimization of folate-conjugated liposomal vectors for folate receptor-mediated gene therapy. J Pharm Sci. 1999;88:1112–1118.
   PubMed Web of Science ®Google Scholar
• Tong L, Chen W, Wu J, et al. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells. Anti Cancer Drugs. 2014;25:244.
   PubMed Web of Science ®Google Scholar
• Wu C, Cao H, Zhou H, et al. Research progress on the antitumor effects of rhein: literature review. Anti Cancer Agents Med Chem. 2015;15:1.
   Google Scholar
• Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem. 1994;269:3198–3204.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Cai Z, Song X, et al. Preparation and characterization of folate conjugated -trimethyl chitosan nanoparticles as protein carrier targeting folate receptor: studies. J Drug Target. 2009;17:294–303.
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Michaelis M, Rothweiler F, et al. Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells. Int J Pharm. 2011;406:128.
   PubMed Web of Science ®Google Scholar
• Desai NP, Tao C, Yang A, et al. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof, US; 2004.
   Google Scholar
• Wu M, Lian B, Deng Y, et al. Resveratrol-loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles wrapping resveratrol nanoparticles: preparation, characterization, and targeting effect on liver tumors. J Biomater Appl. 2017;31:191–205.
   Web of Science ®Google Scholar
• Zhao X, Tang J, Zu Y, et al. Preparation of folate-conjugated bovine serum albumin nanoparticles adsorbing epirubicin hydrochloride. Nano. 2013;08:1350066.
   Web of Science ®Google Scholar
• Wang F, Yang K, Wang Z, et al. Combined image guided monitoring the pharmacokinetics of rapamycin loaded human serum albumin nanoparticles with a split luciferase reporter. Nanoscale. 2016;8:3991–4000.
   PubMed Web of Science ®Google Scholar
• Jose S, Anju SS, Cinu TA, et al. In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery. Int J Pharm. 2014;474:6–13.
   PubMed Web of Science ®Google Scholar
• Kim JS, Kim MS, Park HJ, et al. Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. Int J Pharm. 2008;359:211–219.
   PubMed Web of Science ®Google Scholar
• Medknow. International Journal of Pharmaceutical Investigation. Int J Pharm. 2011;359:211–219.
   Google Scholar
• Huang Z, Sun GB, Chiew YC, et al. Formation of ultrafine aspirin particles through rapid expansion of supercritical solutions (RESS). Powder Technol. 2005;160:127–134.
   Web of Science ®Google Scholar
• Stepanenko AA, Dmitrenko VV. Pitfalls of the MTT assay: direct and off-target effects of inhibitors can result in over/underestimation of cell viability. Gene. 2015;574:193–203.
   PubMed Web of Science ®Google Scholar
• Wang S, Yu H, Wickliffe JK. Limitation of the MTT and XTT assays for measuring cell viability due to superoxide formation induced by nano-scale TiO2. Toxicol In Vitro. 2011;25:2147–2151.
   PubMed Web of Science ®Google Scholar
• Park K, Kim JH, Nam YS, et al. Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. J Control Release. 2007;122:305–314.
   PubMed Web of Science ®Google Scholar